Evidence map›Paper›PMID 32612991›Full record

ArticleFrontiers in cell and developmental biology2020

Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

David F Stroncek, Ping Jin, David H McKenna, Minoko Takanashi, Magali J Fontaine, Shibani Pati, Richard Schäfer, Emily Peterson, Eric Benedetti, Jo-Anna Reems

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. From pathogenesis to therapy: extracellular vesicles in osteoarthritis.Frontiers in bioengineering and biotechnology · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. MSC Manufacture.Advances in experimental medicine and biology · 2025
    Review
  17. Analyte heterogeneity analysis as a possible potency parameter for MSC.Best practice & research. Clinical haematology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David F StroncekCell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States.
Ping JinCell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States.
David H McKennaBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.
Minoko TakanashiBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.
Magali J FontaineBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.
Shibani PatiBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.
Richard SchäferBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.
Emily PetersonCell Therapy and Regenerative Medicine Facility, University of Utah, Salt Lake City, UT, United States.
Eric BenedettiCell Therapy and Regenerative Medicine Facility, University of Utah, Salt Lake City, UT, United States.
Jo-Anna ReemsBiomedical Excellence for Safer Transfusion (BEST), Lebanon, NH, United States.

Funding

Protective Role of Nonclassical Monocytes in Immunotherapies for Solid CancersU01CA224766 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C, KAPLAN, ROSANDRA · 2018 to 2021
$1.4M
Develop novel assays for assessing cellular and gene therapiesZIACL002119 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2010 to 2025
$0k
Development of novel cell and gene therapiesZIACL002120 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2009 to 2025
$0k
NCI NIH HHS U01 CA224766
6 · The paper itself

Abstract

backgroundCulture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when manufactured using different methods and different source materials. The purpose of this study was to assess the impact on MSC characteristics when different laboratories propagated MSCs from cultures initiated with BM aliquots derived from the same donor source material. METHODS AND

methodsFive aliquots from each of three different BM donors were distributed to five independent laboratories. Three laboratories plated whole BM and two laboratories a mononuclear BM cell fraction. Four laboratories cultured in media supplemented with fetal bovine serum (FBS) and one laboratory used human platelet lysate (hPL). Initial cell seeding densities (i.e., P0) ranged from 19.7 × 10

resultsTransit times from BM collection to receipt by laboratories located in the United States ranged from 16.0-30.0 h and from 41.5-71.5 h for a laboratory in Asia. Post-thaw culture derived MSCs rom BM #1, #2, and #3 exhibited viabilities that ranged from 74-92%, 61-96%, and 23-90%, respectively. CFU activity from BM #1, #2, and #3 per 200 MSCs plated averaged 45.1 ± 21.4, 49.3 ± 26.8 and 14.9 ± 13.3, respectively. No substantial differences were observed in immunophenotype, and immunosuppressive activities. Global gene expression profiles of MSCs revealed transcriptome differences due to different inter-laboratory methods and to donor source material with the center effects showing greater molecular differences than source material.

conclusionFunctional and molecular differences exist among MSCs produced by different centers even when the same BM starting material is used to initiate cultures. These results indicated that manufacturing of MSCs by five independent centers contributed more to MSC variability than did the source material of the BM used in this study. Thus, emphasizing the importance of establishing worldwide standards to propagate MSCs for clinical use.

Indexed as

bone marrowmesenchymal stromal cellsqualitytranscriptomevariability

Identifiers

PMID32612991
PMCPMC7308721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.